```html

Zollinger‑Ellison Gastrinoma: A Complete Patient Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare neuroendocrine disorder caused by one or more gastrin‑producing tumors (gastrinomas). These tumors most often arise in the pancreas or duodenum and secrete excess gastrin, a hormone that stimulates the stomach lining to produce large amounts of acid. The resulting hyperacidity leads to severe peptic ulcers, diarrhea, and other gastrointestinal problems.

Who it affects: ZES can occur at any age but most patients are diagnosed between 30 and 60 years old. Men and women are affected equally. Approximately 20–30 % of patients have an inherited form linked to the genetic condition multiple endocrine neoplasia type 1 (MEN‑1).

Prevalence: Gastrinomas are estimated to occur in <sup>1</sup>‑<sub>3</sub> per million people worldwide. Because many cases are discovered incidentally during work‑up for ulcer disease, the true prevalence may be slightly higher. The inherited MEN‑1 form accounts for roughly 20 % of all gastrinomas.<sup>[1][2]</sup>

Symptoms

Symptoms stem from excess gastric acid and from the tumor itself (if large enough). Common and less common manifestations include:

• Recurrent or refractory peptic ulcers – often multiple and located beyond the duodenum (e.g., jejunal ulcers).
• Abdominal pain – a burning or gnawing sensation that may improve after meals (due to ulcer healing) but can become constant as disease progresses.
• Diarrhea – watery, sometimes greasy stools caused by acid inactivation of pancreatic enzymes.
• Steatorrhea (fatty stools) – malabsorption from pancreatic enzyme inhibition.
• Heartburn / gastroesophageal reflux disease (GERD) – due to high gastric volume and acidity.
• Nausea and vomiting – especially after large meals.
• Weight loss – secondary to malabsorption and chronic diarrhea.
• Gastrointestinal bleeding – from ulcer erosion; may present as melena or hematemesis.
• Fever, fatigue, or malaise – if complications such as perforation or infection develop.
• Palpable abdominal mass – rare, typically only with larger tumors.
• Signs of MEN‑1 – hyperparathyroidism (kidney stones, bone pain) or pituitary tumors (headaches, vision changes) in patients with the inherited form.

Causes and Risk Factors

Primary cause

Zollinger‑Ellison syndrome results from a gastrin‑secreting neuroendocrine tumor. The exact trigger for sporadic gastrinomas is unclear, but genetic mutations (e.g., loss of function in the tumor‑suppressor gene MEN1) have been identified in many cases.

Risk factors

• Inherited MEN‑1 syndrome – autosomal dominant; up to 25 % of ZES patients have MEN‑1.
• Family history of gastrinoma or MEN‑1.
• Age – incidence rises after the third decade.
• Previous gastric ulcer disease – not a cause, but many patients are initially misdiagnosed with simple ulcer disease.

Diagnosis

Because symptoms overlap with common ulcer disease, a systematic approach is essential.

Initial evaluation

• Detailed medical history – frequency, location, and healing pattern of ulcers; diarrhea; family history of MEN‑1.
• Physical exam – assessing for abdominal tenderness, masses, or signs of anemia.

Laboratory tests

• Fasting serum gastrin level – markedly elevated (>1000 pg/mL) in >85 % of patients. Levels must be interpreted after withholding proton‑pump inhibitors (PPIs) for at least 1 week.
• Secretin stimulation test – gastrin rises >120 pg/mL after IV secretin; considered the gold standard when fasting gastrin is equivocal.
• Acid output measurement (gastric pH <2) confirms hyperacidity.
• Chromogranin A – a general neuroendocrine tumor marker, useful for monitoring.

Imaging studies

• Endoscopic ultrasound (EUS) – high sensitivity for small pancreatic or duodenal lesions.
• Multiphasic contrast‑enhanced CT or MRI – detects primary tumor and liver metastases.
• Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT – identifies lesions expressing somatostatin receptors, which is helpful for staging and for planning peptide‑receptor radionuclide therapy (PRRT).
• Selective arterial secretin stimulation test – localizes the tumor when non‑invasive imaging is negative.

Pathology

If surgical resection is performed, tissue is examined for tumor grade (well‑differentiated neuroendocrine tumor vs. carcinoma) and Ki‑67 proliferation index, which guide prognosis and therapy.

Treatment Options

Management aims to control acid hypersecretion, remove or control the tumor, and monitor for recurrence or metastasis.

Medical therapy – acid control

• Proton‑pump inhibitors (PPIs) – high‑dose omeprazole, esomeprazole, or pantoprazole are first‑line. Doses often exceed standard ulcer doses (e.g., omeprazole 80–120 mg daily) and may need lifelong continuation.<sup>[3]</sup>
• H2‑receptor antagonists – less effective than PPIs but can be adjuncts.

Effective acid suppression heals existing ulcers and prevents new ones, dramatically improving quality of life.

Surgical options

• Localized tumor resection – pancreaticoduodenectomy (Whipple) or limited enucleation when the tumor is small and confined.
• Debulking surgery – for metastatic disease to reduce tumor burden and gastrin output.
• Metastatectomy – removal of liver lesions when feasible.

Surgery offers the only potential cure for localized gastrinomas; 5‑year survival exceeds 80 % when complete resection is achieved.

Medical oncology for metastatic disease

• Somatostatin analogues (octreotide, lanreotide) – bind somatostatin receptors, decreasing gastrin secretion and sometimes shrinking tumors.
• Targeted therapy – everolimus (mTOR inhibitor) approved for advanced pancreatic neuroendocrine tumors.
• Peptide‑receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE delivers radiation directly to receptor‑positive cells; improves progression‑free survival.
• Chemotherapy – reserved for high‑grade, poorly differentiated neuroendocrine carcinomas (e.g., cisplatin + etoposide).

Lifestyle and supportive measures

• Avoid NSAIDs, aspirin, and alcohol, which aggravate ulcer formation.
• Eat small, frequent meals; low‑fat diet can reduce diarrhea.
• Stay hydrated and consider pancreatic enzyme supplements if steatorrhea persists.
• Regular bone‑density screening if MEN‑1 related hyperparathyroidism is present.

Living with Zollinger‑Ellison Gastrinoma

Medication management

• Take PPIs exactly as prescribed – usually 1–2 tablets twice daily, with timing flexible (with or without food).
• Keep a medication diary to track symptom relief and any side effects.
• Never stop PPIs abruptly without medical guidance; rebound acid hypersecretion can occur.

Nutrition tips

• Focus on a balanced diet rich in lean protein, whole grains, and non‑citrus fruits.
• Limit caffeine, carbonated drinks, and very spicy foods that may increase gastric irritation.
• If diarrhea is troublesome, try a low‑FODMAP diet and discuss enzyme replacement with your gastroenterologist.

Follow‑up schedule

• Every 3–6 months: serum gastrin, chromogranin A, and liver function tests.
• Annual imaging (MRI or CT) to surveil for recurrence or metastasis.
• Genetic counseling for patients with MEN‑1 or a family history.

Psychosocial support

Living with a rare tumor can be stressful. Consider joining patient‑support groups (e.g., Neuroendocrine Tumor (NET) Patient Foundation) and seek mental‑health counseling if anxiety or depression arise.

Prevention

Because most gastrinomas are sporadic, primary prevention is limited. However, you can reduce complications and possibly lower risk of tumor progression:

• Maintain a healthy weight and avoid tobacco – smoking is linked to neuroendocrine tumor aggressiveness.
• For those with known MEN‑1, undergo regular screening (annual fasting gastrin, imaging) to detect tumors early.
• Promptly treat Helicobacter pylori infection and avoid chronic NSAID use, which can mask ulcer symptoms and delay diagnosis.

Complications

If untreated or inadequately controlled, ZES can lead to serious health problems:

• Refractory or perforated peptic ulcers – may require emergency surgery.
• Gastrointestinal bleeding – can cause anemia or hemodynamic instability.
• Severe malabsorption – resulting in nutrient deficiencies (vitamins A, D, E, K, B12) and osteoporosis.
• Pancreatic or liver metastases – occur in 50–60 % of patients at diagnosis; they reduce survival rates.
• Gastric carcinoid tumors – chronic hypergastrinemia stimulates entero‑chromaffin‑like cell proliferation.
• MEN‑1 associated cancers – hyperparathyroidism, pituitary adenomas, and other endocrine neoplasms.

When to Seek Emergency Care

References

1. Jonkman J, et al. "Zollinger‑Ellison syndrome: clinical features and management." World J Gastroenterol. 2020;26(1):23‑33.
2. American College of Gastroenterology. "Guidelines for the Management of Gastric Hypersecretory Disorders." 2022.
3. Mayo Clinic. "Zollinger‑Ellison syndrome." Updated 2023. https://www.mayoclinic.org
4. National Comprehensive Cancer Network (NCCN). "Neuroendocrine and Pancreatic Tumors Guidelines," Version 3.2024.
5. World Health Organization. "Classification of Tumours of the Digestive System, 5th Edition." 2022.

```